{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:47:07Z","timestamp":1772488027172,"version":"3.50.1"},"reference-count":32,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"unspecified","delay-in-days":128,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>HIV-1 drug resistance can compromise the effectiveness of antiretroviral therapy (ART). A survey of pretreatment HIV-1 drug resistance (PDR) was conducted in Lincang Prefecture of Yunnan Province. From 372 people living with HIV\/AIDS initiating ART for the first time during 2017\u20132018, 322 <jats:italic>pol<\/jats:italic> sequences were obtained, of which 11 HIV-1 strain types were detected. CRF08_BC (70.2%, 226\/322) was the predominant strain, followed by URF strains (10.6%, 34\/322). Drug resistance mutations (DRMs) were detected among 34.2% (110\/322) of the participants. E138A\/G\/K\/R (14.3%, 46\/322) and V179E\/D\/T (13.7%, 47\/322) were the predominant DRMs. Specifically, E138 mutations commonly occurred in CRF08_BC (19.9%, 45\/226). Among the DRMs detected, some independently conferred resistance, such as K65R (1.6%, 5\/322), Y188C\/F\/L (0.9%, 3\/322), K103N (0.6%, 2\/322) and G190A (0.3%, 1\/322), which conferred high-level resistance. The prevalence of PDR was 7.5% (95% CI: 4.6\u201310.3%) and the prevalence of non-nucleotide reverse transcriptase inhibitor (NNRTI) resistance was 5.0% (95% CI: 2.6\u20137.4%), which is below the threshold (\u2a7e10%) of initiating a public health response. In conclusion, HIV-1 genetic diversity and an overall moderate level of PDR prevalence were found in western Yunnan. PDR surveillance should be continually performed to decide whether a public health response to NNRTI resistance should be initiated.<\/jats:p>","DOI":"10.1017\/s095026882000093x","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:05:16Z","timestamp":1588910716000},"source":"Crossref","is-referenced-by-count":21,"title":["The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China"],"prefix":"10.1017","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9699-7524","authenticated-orcid":false,"given":"Min","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manhong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-3636","authenticated-orcid":false,"given":"Yanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"S095026882000093X_ref32","unstructured":"32. China National Health Commission. Notice on issuing the list of 1st batch of encouraged generic drugs Available at http:\/\/www.nhc.gov.cn\/yaozs\/s7656\/201910\/38e3961482c04b59a2aa3e36106b1a4f.shtml. Accessed 17 September 2019."},{"key":"S095026882000093X_ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29202-2"},{"key":"S095026882000093X_ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"Journal of the International AIDS Society"},{"key":"S095026882000093X_ref27","volume-title":"Antiretroviral Resistance in Clinical Practice","author":"Mackie","year":"2006"},{"key":"S095026882000093X_ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030443"},{"key":"S095026882000093X_ref24","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0233"},{"key":"S095026882000093X_ref23","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0252"},{"key":"S095026882000093X_ref20","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0053"},{"key":"S095026882000093X_ref11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12879-019-3927-1","article-title":"Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Infectious Diseases"},{"key":"S095026882000093X_ref10","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017)","volume":"18","author":"Zuo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"S095026882000093X_ref1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infectious diseases"},{"key":"S095026882000093X_ref3","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/jac\/dky278","article-title":"Pretreatment HIV drug resistance among adults initiating ART in Namibia","volume":"73","author":"Taffa","year":"2018","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"S095026882000093X_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw445"},{"key":"S095026882000093X_ref9","unstructured":"9. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens Available at https:\/\/www.who.int\/hiv\/pub\/arv\/arv-update-2019-policy\/en\/. Accessed July 2019."},{"key":"S095026882000093X_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky221"},{"key":"S095026882000093X_ref31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1570162X17666191128101426","article-title":"Survey of pretreatment HIV drug resistance and genetic transmission network analysis among HIV patients in a high drug-use area of Southwest China","volume":"17","author":"Liu","year":"2019","journal-title":"Current HIV Research"},{"key":"S095026882000093X_ref8","unstructured":"8. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance Available at http:\/\/www.who.int\/hiv\/topics\/drugresistance\/en. Accessed 7 July 2017."},{"key":"S095026882000093X_ref12","first-page":"648","article-title":"HIV-1 drug resistance and influencing factors among people living with HIV\/AIDS before antiretroviral therapy in Liangshan Yi Autonomous Prefecture","volume":"40","author":"Dong","year":"2019","journal-title":"Chinese Journal of Epidemiology"},{"key":"S095026882000093X_ref29","first-page":"722","article-title":"HIV-1 genetics and drug resistance threshold survey in Lincang City of Yunnan Province in 2012","volume":"19","author":"Chen","year":"2013","journal-title":"Chinese Journal of AIDS and STD"},{"key":"S095026882000093X_ref7","unstructured":"7. World Health Oganization. HIV drug resistance report 2019 Available at https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2019\/en\/. Accessed July 2019."},{"key":"S095026882000093X_ref13","doi-asserted-by":"publisher","DOI":"10.1038\/455609a"},{"key":"S095026882000093X_ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4276-9"},{"key":"S095026882000093X_ref6","first-page":"1749","article-title":"Pretreatment HIV drug resistance increases regimen switches in sub-saharan Africa","volume":"61","author":"Boender","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"S095026882000093X_ref18","unstructured":"18. World Health Organization. Surveillance of HIV drug resistance in adults initiating antiretroviral therapy (pre-treatment HIV drug resistance) Available at http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112802\/9789241507196_eng.pdf?sequence=1. Accessed July 2014."},{"key":"S095026882000093X_ref15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12879-018-3130-9","article-title":"High prevalence of HIV-1 transmitted drug resistance among therapy-naive Burmese entering travelers at Dehong ports in Yunnan, China","volume":"18","author":"Xuan","year":"2018","journal-title":"BMC Infectious Diseases"},{"key":"S095026882000093X_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"S095026882000093X_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30119-9"},{"key":"S095026882000093X_ref22","first-page":"e00315","article-title":"Genome sequences of a novel HIV-1 circulating recombinant form (CRF59_01B) identified among men who have sex with men in Northeastern China","volume":"1","author":"Han","year":"2013","journal-title":"Genome Announcements"},{"key":"S095026882000093X_ref16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/1471-2334-12-382","article-title":"Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Infectious Diseases"},{"key":"S095026882000093X_ref19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/aid.2017.0288","article-title":"Characterization of a novel HIV-1 circulating recombinant rorm, CRF01_AE\/B'\/C (CRF96_cpx), in Yunnan, China","volume":"34","author":"Miao","year":"2018","journal-title":"AIDS Research and Human Retroviruses"},{"key":"S095026882000093X_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92304-3"},{"key":"S095026882000093X_ref21","first-page":"e00050","article-title":"Genome sequences of a novel HIV-1 circulating recombinant form, CRF55_01B, identified in China","volume":"1","author":"Han","year":"2013","journal-title":"Genome Announcements"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S095026882000093X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T03:10:50Z","timestamp":1590981050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S095026882000093X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"alternative-id":["S095026882000093X"],"URL":"https:\/\/doi.org\/10.1017\/s095026882000093x","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"e102"}}